MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor

被引:92
|
作者
Liu, Lingxiang [1 ]
Shao, Xiaoyan [2 ]
Gao, Wen [1 ]
Zhang, Zhi [3 ]
Liu, Ping [1 ]
Wang, Rongsheng [1 ]
Huang, Puwen [1 ]
Yin, Yongmei [1 ]
Shu, Yongqian [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Ctr Canc, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Univ, Sch Med, Affiliated DrumTower Hosp, Dept Hematol, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Canc Hosp, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
epidermal growth factor receptor (EGFR); microRNA; miR-133b; non-small-cell lung cancer; targeted therapy; DIFFERENTIAL EXPRESSION; CLINICAL-RESPONSE; EGFR EXPRESSION; COPY NUMBER; IN-VITRO; GEFITINIB; MIR-133B; SURVIVAL; GENE; MUTATIONS;
D O I
10.1111/j.1742-4658.2012.08741.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Both the deregulation of microRNAs and epidermal growth factor receptor (EGFR) are emerging as important factors in non-small-cell lung cancer (NSCLC). Here, miR-133b was found to be associated with tumor stage, the extent of regional lymph node involvement, stage, visceral pleura or vessel invasion and EGFR mRNA expression in Chinese patients with NSCLC. Bioinformatic analysis and luciferase reporter assay revealed that miR-133b can interact specifically with the 3'-UTR of EGFR mRNA. Functionally, miR-133b transfection showed regulatory activity in translationally repressing EGFR mRNA. Moreover, miR-133b transfection may modulate apoptosis, invasion and sensitivity to EGFR-TKI through the EGFR signaling pathways, especially in EGFR-addicted NSCLC cells. Taken together, our findings show that miR-133b can inhibit cell growth of NSCLC through targeting EGFR and regulating its downstream signaling pathway. This finding has important implications for the development of targeted therapeutics for a number of EGFR-addicted cancers.
引用
收藏
页码:3800 / 3812
页数:13
相关论文
共 50 条
  • [41] Downregulation Of microRNA-133b And Its Clinical Value In Non-Small Cell Lung Cancer
    Chen, Guan-yu
    Ruan, Lin
    ONCOTARGETS AND THERAPY, 2019, 12 : 9421 - 9434
  • [42] Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors
    Tsuboi, M
    Le Chevalier, T
    MEDICAL ONCOLOGY, 2006, 23 (02) : 161 - 170
  • [43] MicroRNA-133b inhibits connective tissue growth factor in colorectal cancer and correlates with the clinical stage of the disease
    Guo, Yihang
    Li, Xiaorong
    Lin, Changwei
    Zhang, Yi
    Hu, Gui
    Zhou, Jianyu
    Du, Juan
    Gao, Kai
    Gan, Yi
    Deng, Hao
    MOLECULAR MEDICINE REPORTS, 2015, 11 (04) : 2805 - 2812
  • [44] Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer
    Na, Im Il
    Kim, Hye-Ryoun
    Lee, Jin Kyung
    Park, Sun Hoo
    Kim, Cheol Hyeon
    Koh, Jae Soo
    Baek, Hee Jong
    Choe, Du Hwan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2012, 8 (03) : 373 - 378
  • [45] Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2013, 76 (05) : 249 - 257
  • [46] Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation
    Oikawa, Takefumi
    Ohira, Tatsuo
    Otani, Keishi
    Hagiwara, Masaru
    Konaka, Chimori
    Ikeda, Norihiko
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 329 - 333
  • [47] Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation
    Jurisic, Vladimir
    Obradovic, Jasmina
    Pavlovic, Sonja
    Djordjevic, Natasa
    ANALYTICAL CELLULAR PATHOLOGY, 2018, 2018
  • [48] Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology
    Jänne, PA
    Engelman, JA
    Johnson, BE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) : 3227 - 3234
  • [49] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch, TJ
    Bell, DW
    Sordella, R
    Gurubhagavatula, S
    Okimoto, RA
    Brannigan, BW
    Harris, PL
    Haserlat, SM
    Supko, JG
    Haluska, FG
    Louis, DN
    Christiani, DC
    Settleman, J
    Haber, DA
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21): : 2129 - 2139
  • [50] Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
    De Luca, A.
    Normanno, N.
    CURRENT DRUG TARGETS, 2010, 11 (07) : 851 - 864